SCHEMBL5453676

SCHEMBL5453676

COc1cc(Nc2ncnc3sc(C)c(C)c23)cc(OC)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.63
SMN1; SMN2 Q16637 5/20 0.63
MAPK1 P28482 4/20 0.63
RAF1 P04049 3/20 0.63
HTT P42858 2/20 0.63
HPGD P15428 1/20 0.63
NPSR1 Q6W5P4 2/20 0.62
ALDH1A1 P00352 1/20 0.62
GAA P10253 1/20 0.60
PIP4K2C Q8TBX8 1/20 0.55
TP53 P04637 1/20 0.55
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
LMNA P02545 2/20 0.54
CSNK2A2 P19784 1/20 0.54
CSNK2B P67870 1/20 0.54
CSNK2A1 P68400 1/20 0.54
OPRM1 P35372 1/20 0.53
OPRD1 P41143 1/20 0.53
MKNK1 Q9BUB5 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5336669 0.82 MAPT (0.54) MAPTSMN1; SMN2MAPK1RAF1HTT
SCHEMBL5467182 0.80 MAPT (0.56) MAPTSMN1; SMN2MAPK1RAF1HTT
SCHEMBL5334693 0.78 TP53 (0.68) MAPTMAPK1HTTHPGDALDH1A1
SCHEMBL3799566 0.77 MAPT (0.61) MAPTSMN1; SMN2MAPK1RAF1HTT
SCHEMBL13164963 0.77 MAPK1 (1.00) MAPTSMN1; SMN2MAPK1RAF1HTT
SCHEMBL5467523 0.77 RAB9A (0.76) MAPTMAPK1HTTHPGDNPSR1
SCHEMBL3804302 0.76 MAPT (0.64) MAPTSMN1; SMN2MAPK1RAF1HTT
SCHEMBL3803118 0.75 MKNK2 (0.60) MKNK1MKNK2
SCHEMBL13165061 0.73 SMN1; SMN2 (0.64) MAPTSMN1; SMN2MAPK1RAF1HTT
SCHEMBL15426163 0.73 FGFR1 (0.67) LMNACSNK2A2CSNK2BCSNK2A1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, API5 MAPT 4267/4885SMN1; SMN2 3131/4885MAPK1 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.